ER and PR expression data were available for 90 of the 112 EnOC cases characterised by WES (Fig. 1 )24 (link). IHC for PR and ER was performed on human tissue microarrays comprising three 0.8 mm cores per case, as previously described24 (link). IHC used 1:50 mouse anti-PR antibody M3569 clone PgR-636 and 1:50 rabbit anti-ER antibody M3643 clone EP1; PR and ER IHC was performed on the Leica BOND III Autostainer and expression was assessed by histoscore, a quantitative nuclear expression score incorporating staining intensity and proportion of positive tumour nuclei31 (link). HREP-based subtype was available for 74 cases from the unsupervised subtyping study24 (link);16 further cases were classified based on their PR and ER histoscore using a threshold of histoscore ≥150 for positivity, as indicated by the unsupervised subtyping study24 (link) (Fig. 1 ).
p53 IHC data were available for 87 of the 90 cases23 (link). IHC was performed on the Leica BOND III Autostainer using a 1:50 dilution of p53 antibody (clone DO-7, DAKO). Wild-type pattern was defined as variable nuclear staining intensity, while aberrant staining was defined as strong diffuse nuclear positivity (aberrant positive) or complete absence of nuclear staining (aberrant null).
p53 IHC data were available for 87 of the 90 cases23 (link). IHC was performed on the Leica BOND III Autostainer using a 1:50 dilution of p53 antibody (clone DO-7, DAKO). Wild-type pattern was defined as variable nuclear staining intensity, while aberrant staining was defined as strong diffuse nuclear positivity (aberrant positive) or complete absence of nuclear staining (aberrant null).
Free full text: Click here
